GlassScriptPhysician profile
Ann Parker
NPI 1588965784
$2,018.68
in general payments reported to CMS, 2019-2025
18 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $374 · 2023: $678 · 2024: $395 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $378.08 | 2022-2025 | Envarsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.58 | 2023-2025 | Xifaxan |
| Abbvie INC. | $275.39 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $183.02 | 2023-2025 | Terlivaz |
| Gilead Sciences, INC. | $160.42 | 2022-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $143.93 | 2022-2023 | Livtencity |
| Sanofi-Aventis U.S. LLC | $137.32 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $82.35 | 2023 | Ultomiris, Soliris |
| Merck Sharp & Dohme LLC | $53.85 | 2025 | Prevymis |
| Novo Nordisk INC | $46.40 | 2021-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $44.95 | 2024-2025 | |
| Melinta Therapeutics, LLC | $31.55 | 2024 | Rezzayo, Vabomere |
| Astellas Pharma US INC | $30.41 | 2025 | Cresemba |
| Vapotherm INC | $24.33 | 2021 | |
| Aurinia Pharma U.S., INC. | $24.12 | 2024 | Lupkynis |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $23.10 | 2023 | Quikclot |
| Madrigal Pharmaceuticals | $20.24 | 2024 | Resmetirom |
| Boston Scientific Corporation | $19.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.